Navigation Links
Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
Date:11/16/2011

SAN MATEO, Calif., Nov. 16, 2011 /PRNewswire/ -- Nile Therapeutics, Inc. (OTCQB: NLTX), a biopharmaceutical company that develops novel therapeutics for heart failure patients, today announced top-line data from its recently completed Phase I clinical trial evaluating the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of subcutaneous bolus and subcutaneous infusion of cenderitide in patients with chronic heart failure. Nile is developing cenderitide as a 90-day outpatient treatment for heart failure patients following admission for acutely decompensated heart failure (ADHF), referred to as the "post-acute" treatment period.

The Phase I clinical trial was designed to understand the doses required to achieve pre-determined plasma levels of cenderitide when delivered through a subcutaneous infusion pump. The target cenderitide plasma levels were based on Nile's previous Phase 2 clinical trials in which cenderitide was delivered through continuous intravenous infusion. In Part A of the trial, 12 patients received two subcutaneous bolus injections of cenderitide.  In Part B of the trial, 34 patients received a 24-hour continuous subcutaneous infusion of either of two fixed doses of cenderitide or placebo. In Part C, 12 patients received a 24-hour continuous subcutaneous infusion of either a weight-based dose of cenderitide, or placebo. All infusions were delivered through subcutaneous pump technology of Medtronic, Inc. pursuant to the parties' February 2011 development collaboration agreement.

The top line results from the Phase 1 trial are as follows:

  • The primary end-point was met – cenderitide achieved target PK levels when delivered through Medtronic's subcutaneous pump technology;
  • 24 hour subcutaneous delivery of ceneritide through Medtronic's pump technology was well-tolerated, with no injection site irritation;
  • Subcutaneously delivered cenderitide has an acc
    '/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Nile Therapeutics Reports 2011 Third Quarter Financial Results
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Orexigen® Therapeutics Reports Third Quarter Financial Results
4. Silence Therapeutics Provides Corporate and Development Update
5. Halozyme Therapeutics Reports Third Quarter 2011 Financial Results
6. Regado Biosciences, Inc. Presents Positive Efficacy and Safety Substudy Data from the Phase 2b RADAR Trial for the REG1 Anticoagulation System at the Transcatheter Cardiovascular Therapeutics (TCT) Symposium 2011
7. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
8. Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
9. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
10. Amsterdam Molecular Therapeutics Provides Operations Update & Strategic Review of Pipeline
11. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Roka Bioscience, Inc. (NASDAQ: ROKA ), a ... the detection of foodborne pathogens, today announced that Paul ... th Annual Healthcare Conference on December 2, 2014 at ... York Palace in New York, NY . ... Company, its operations, strategies and prospects may be discussed. To ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... focused on developing diagnostic tests for cancer and other conditions, ... will be presented at the Science for Business BioWin Day ... Belgium . The data come from VolitionRx,s lung cancer ... Pneumology department of the Centre Hospitalier Universitaire (CHU) de Liege ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Continental ... patient populations into clinical trials at its mid-Atlantic ... , “Continental was created with the idea of ... a fundamental role in medical advances," said Continental's ... syphilis experiment to the immortal cell line of ...
(Date:11/24/2014)... 2014 Senior Vice President, General ... leadership skills, business acumen Elsevier , ... products and services, congratulates Diane Bartoli , Senior ... Workflow, Elsevier Clinical Solutions, for being recognized in the ... Awards issue of Profiles in Diversity Journal ...
Breaking Biology Technology:Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 2Elsevier Clinical Solutions' Diane Bartoli Featured In Profiles in Diversity Journal's 13th Annual Women Worth Watching Issue 3
... and Families, EMERYVILLE, Calif., April 15 ... two new health care areas designed to,soothe patients ... to offer health resources. The Carol Ann,Read Breast ... procedures, all in one location, for the quickest ...
... Able to Detect a Single Cancer Cell Through In Vivo ... ... Caliper Life,Sciences, Inc. (Nasdaq: CALP ) today introduced Bioware(R) Ultra cell ... in vivo imaging applications. Bioware Ultra cell lines are,10 to 100 times ...
... Pittsburgh-based Foundation,Radiology Group (FRG), a full-service ... diagnostic images for hospitals,announced today that James ... the,position of Chief Medical Officer. The appointment ... nationwide network of radiology physician groups to,provide ...
Cached Biology Technology:Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 2Alta Bates Summit Medical Center Opens Two Warm, Supportive Patient Centers: Carol Ann Read Breast Health Center and Family Resource Center 3Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 2Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines 3James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 2James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group 3
(Date:11/4/2014)... of Medicine announced today that it is a ... the Bill & Melinda Gates Foundation. Laura ... Reproductive Sciences; and Vice Chair of Research and ... will pursue an innovative global health and development ... Fetal Neurodevelopment.", Grand Challenges Explorations (GCE) funds individuals ...
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
Breaking Biology News(10 mins):Temple University School of Medicine receives Grand Challenges Explorations grant 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3The 'valley of death' facing physics start-ups 2
... that some biological structures, like the brain or the ... explain. Biologists have proposed various ways that so-called ,irreducibly ... bit. But a new study proposes an alternative route. ... becoming more intricate, say authors Dan McShea and Wim ...
... Ohio American adults who prepare their own meals and ... on one of those activities at the expense of the ... a 10-minute increase in food preparation time was associated with ... for both men and women. The finding applied to single ...
... helpers (nannies) in a cichlid fish allow the dominant male ... and territory, according to new research published today in ... 30 days which corresponds to one breeding cycle in ... and the University of Bern (Switzerland) studied the investment strategies ...
Cached Biology News:Study proposes alternative way to explain life's complexity 2Study proposes alternative way to explain life's complexity 3Exercise or make dinner? Study finds adults trade one healthy act for another 2Exercise or make dinner? Study finds adults trade one healthy act for another 3
IHC detection kit for PCNA in cells and tissues...
... Immunogen: Synthetic peptide derived from the ... protein. Specificity: Reacts with the ... Reactivity: Human Mouse (positive controls: WNT1-transfected ... lysates and mouse Mouse-1 cell lysates). ...
The pYES2 vector is designed for native expression of your protein of interest in S. cerevisiae. It contains the URA3 gene for selection in yeast and 2 origin for high-copy maintenance....
... cAMP - [125I] Direct SPA ... SPA.Includes lysis reagents that eliminate lengthy ... cAMP measurement (optional use).Range: 1.32-84.28 ng/ml ... pmol/ml).Overnight protocol.Store at 2-8 C. Category: ...
Biology Products: